Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market ...

The U.S. Food and Drug Administration is moving to fast-track reviews of two experimental Merck drugs with ...

Merck (MRK) closed at $106.45 in the latest trading session, marking a +1.34% move from the prior day. This change outpaced the S&P 500's 0.32% gain on the day. Elsewhere, the Dow saw an upswing of 0.

“Following the initial pause, the FDA has placed the trial on a partial clinical hold,” the spokesperson explained.

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Merck & Co. is turning down its option to license Evaxion’s gonorrhea vaccine candidate, closing the door on the Danish ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few ...

FDA plans to fast-track reviews of two experimental Merck drugs under its priority voucher program, potentially accelerating ...

Pfizer & Merck are the boring intentional reset w/flat growth expectations. Pfizer now offers high dividends, Merck offers ...

When Nicole Stovall stepped into her new role as Chief Diversity Officer at Merck, it wasn’t just another career milestone—it was the manifestation of years of purpose, persistence, and faith […] ...

Merck (MRK) stock gains as BMO Capital Markets upgrades the company to Outperform citing strong portfolio moves before ...

Dr. Rasha Kelej meets The First Lady of Liberia & 6 African First Ladies of Africa at the 12th Africa Asia Luminary 2025 in ...